<DOC>
	<DOCNO>NCT02227797</DOCNO>
	<brief_summary>The primary purpose study identify optimal dose voriconazole , anti-fungal drug often used people undergo stem cell transplant . An optimal dose level one level provide good blood level ( concentration ) voriconazole without much toxicity .</brief_summary>
	<brief_title>MT2013-37R : Voriconazole Monitoring Pediatric Stem Cell Transplant Patients</brief_title>
	<detailed_description />
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<criteria>Any patient undergoing allogeneic hematopoietic stem cell transplantation ( either 1st subsequent ) Age ≤ 21 year Adequate organ function within 14 day enrollment , i.e . Creatinine : &lt; 1.5 x ULN Hepatic : ALT , AST total bilirubin &lt; 3 x ULN Requires voriconazole prevent treat invasive fungal infection undergo stem cell transplantation Has receive voriconazole within 5 day prior start study therapy History hypersensitivity severe intolerance azoles History , current evidence , cardiac arrhythmia define QTc ≥ 480 mm/sec Receiving follow drug discontinue least 24 hour start therapy : pimozide , quinidine , astemizole , ergot alkaloid . Received one follow drug within 14 day prior start study , potent inducer hepatic microsomal enzyme : rifampin , rifabutin , carbamazepine , phenytoin , nevirapine , longacting barbiturate . Received sirolimus within 14 day prior start study voriconazole potent inhibitor sirolimus metabolism Receiving anticipate need methadone coadministration voriconazole potentially increase methadone exposure</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>stem cell transplant</keyword>
	<keyword>hematopoietic stem cell transplant</keyword>
	<keyword>fungal infection</keyword>
	<keyword>voriconazole</keyword>
	<keyword>pediatric</keyword>
</DOC>